MONET and MONOI have shown a small rise in cholesterol after stopping tenofovir in darunavir/ritonavir arm, without providing any information regarding endothelial function. We performed a study to compare the change in brachial artery flow mediated vasodilatation in patients receiving darunavir/ritonavir monotherapy versus triple therapy.
A randomized, controlled trial to evaluate change in cardiometabolic and endothelial function in HIV-infected patients with optimal viral suppression on Darunavir/ritonavir monotherapy vs. triple-therapy / Guaraldi, Giovanni; Zona, Stefano; Cossarizza, Andrea; L., Vernacotola; Carli, Federica; A., Lattanzi; Beghetto, Barbara; Orlando, Gabriella; R., Termini; M., Garau. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - STAMPA. - 16:(2011), pp. A43-A44. ((Intervento presentato al convegno 13th international workshop on Adverse Drug Reactions and Co-morbidities in HIV. tenutosi a Rome nel 14-16 Jul 2011.
A randomized, controlled trial to evaluate change in cardiometabolic and endothelial function in HIV-infected patients with optimal viral suppression on Darunavir/ritonavir monotherapy vs. triple-therapy.
GUARALDI, Giovanni;ZONA, Stefano;COSSARIZZA, Andrea;CARLI, FEDERICA;BEGHETTO, Barbara;ORLANDO, Gabriella;
2011
Abstract
MONET and MONOI have shown a small rise in cholesterol after stopping tenofovir in darunavir/ritonavir arm, without providing any information regarding endothelial function. We performed a study to compare the change in brachial artery flow mediated vasodilatation in patients receiving darunavir/ritonavir monotherapy versus triple therapy.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
